Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection
Cureus,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 17, 2024
This
case
report
aims
to
elucidate
the
unique
clinical
course
of
a
34-year-old
male
patient
diagnosed
with
human
immunodeficiency
virus
(HIV),
chronic
hepatitis
C,
and
prior
tuberculosis
(TB)
infections,
who
subsequently
contracted
COVID-19.
Immunological
assessments
revealed
profound
immunosuppression,
marked
by
decreased
CD4+
T
cells
(0.037
x
10⁹/L),
alongside
mildly
elevated
IgG
levels
(16.701
g/L),
reflecting
both
HIV-related
non-adherence
antiretroviral
therapy
(ART).
Concurrently,
tested
positive
for
SARS-CoV-2.
Imaging
findings
demonstrated
overlapping
characteristics
TB
Timely
initiation
specific
therapy,
supportive
care
optimized
anti-TB
regimens,
was
implemented.
Despite
patient's
immunocompromised
state
complex
medical
history,
he
successfully
recovered
from
Key
factors
contributing
survival
included
early
diagnosis
treatment,
comprehensive
care,
careful
management
drug
interactions,
potentially
effective
individual
immune
response.
Notably,
no
typical
features
COVID-19
pneumonia
were
observed,
suggesting
that
dual
infection
may
have
influenced
presentation.
underscores
potential
outcomes
in
individuals
histories,
including
coexisting
infections.
Further
research
into
interplay
multiple
infections
such
patients
is
warranted
optimize
strategies
enhance
our
understanding
within
this
distinctive
population.
Язык: Английский
Differential control of mycobacteria among COVID-19 patients is associated with CD28+ CD8+ T cells
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 10, 2024
ABSTRACT
Diseases
caused
by
SARS-CoV-2
and
Mycobacterium
tuberculosis
(
M.tb
)
represent
two
public
health
emergencies.
In
severe
disease,
both
pathogens
may
share
a
biological
niche
in
the
lower
respiratory
tract.
There
is
significant
potential
for
infections
to
be
co-present
within
individuals
enhance
or
moderate
respective
outcomes
of
either
infection.
Here,
we
investigated
how
whole
blood
samples,
as
well
CD4+
CD8+
T
cells,
from
hospitalised
with
acute
COVID-19
disease
respond
mycobacterial
challenge.
To
do
this,
samples
were
assessed
ex
vivo
growth
inhibition
assays,
immune
cell
phenotyping
mass
cytometry,
cytokine
responses
antigens
flow
cytometry.
These
studies
identified
subgroup
patients
whose
had
an
enhanced
capacity
inhibit
growth.
The
ability
control
was
associated
presence
non
-specific
CD28+
population,
particular
activation
status
migratory
phenotype.
This
work
improves
our
understanding
factors
involved
control,
contribute
design
novel
therapies
TB.
Язык: Английский